January 28, 2021 Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer View Article
September 18, 2020 Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020 View Article
